Geode Capital Management LLC increased its stake in shares of Alkermes Plc (NASDAQ:ALKS) by 1.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,333,429 shares of the company’s stock after buying an additional 21,608 shares during the quarter. Geode Capital Management LLC’s holdings in Alkermes were worth $72,934,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. First Trust Advisors LP grew its position in Alkermes by 18.6% during the fourth quarter. First Trust Advisors LP now owns 800,752 shares of the company’s stock worth $43,825,000 after buying an additional 125,309 shares in the last quarter. Bailard Inc. acquired a new stake in Alkermes during the fourth quarter worth approximately $274,000. Schwab Charles Investment Management Inc. grew its position in Alkermes by 5.0% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 493,515 shares of the company’s stock worth $27,011,000 after buying an additional 23,712 shares in the last quarter. Janus Henderson Group PLC grew its position in Alkermes by 13.7% during the third quarter. Janus Henderson Group PLC now owns 2,650,006 shares of the company’s stock worth $134,726,000 after buying an additional 319,014 shares in the last quarter. Finally, AMP Capital Investors Ltd grew its position in Alkermes by 11.0% during the third quarter. AMP Capital Investors Ltd now owns 53,745 shares of the company’s stock worth $2,732,000 after buying an additional 5,306 shares in the last quarter.
In other news, SVP Laurie Keating sold 6,249 shares of the stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total value of $757,378.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Shane Cooke sold 72,793 shares of the stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $60.55, for a total value of $4,407,616.15. Following the completion of the transaction, the insider now owns 147,501 shares of the company’s stock, valued at $8,931,185.55. The disclosure for this sale can be found here. In the last ninety days, insiders sold 125,433 shares of company stock worth $7,942,327. Company insiders own 5.34% of the company’s stock.
A number of brokerages recently issued reports on ALKS. Credit Suisse Group set a $66.00 price target on Alkermes and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Morgan Stanley reissued an “equal weight” rating and set a $67.00 price target (up previously from $60.00) on shares of Alkermes in a research report on Friday, February 23rd. Cantor Fitzgerald reissued a “hold” rating and set a $50.00 price target on shares of Alkermes in a research report on Tuesday, February 20th. Citigroup set a $62.00 price target on Alkermes and gave the stock a “hold” rating in a research report on Thursday, February 15th. Finally, Zacks Investment Research raised Alkermes from a “hold” rating to a “buy” rating and set a $61.00 price target on the stock in a research report on Monday, January 8th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Alkermes has a consensus rating of “Hold” and an average price target of $64.58.
Shares of Alkermes Plc (NASDAQ:ALKS) opened at $60.35 on Wednesday. The firm has a market capitalization of $9,322.16, a price-to-earnings ratio of -58.59 and a beta of 1.87. Alkermes Plc has a twelve month low of $46.42 and a twelve month high of $71.22. The company has a quick ratio of 2.46, a current ratio of 2.78 and a debt-to-equity ratio of 0.23.
Alkermes (NASDAQ:ALKS) last issued its earnings results on Wednesday, February 14th. The company reported $0.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.32. The firm had revenue of $275.37 million for the quarter, compared to the consensus estimate of $251.23 million. Alkermes had a negative return on equity of 4.32% and a negative net margin of 17.48%. The company’s revenue was up 29.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.02 EPS. equities research analysts expect that Alkermes Plc will post -0.8 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/03/14/geode-capital-management-llc-has-72-93-million-position-in-alkermes-plc-alks.html.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.